Compare Cintas Corporation (CTAS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Sana Biotechnology Inc — how do they compare? Cintas Corporation trades at $205.78 (market cap $82.15B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Cintas Corporation is far larger — about 72.7× Sana Biotechnology Inc's market cap, and Cintas Corporation pays a 1.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CTAS | SANA | |
|---|---|---|
Market Cap | $82.15B | $1.13B |
Sector | Industrials | Health |
52-Week High | $225.10 | $5.92 |
52-Week Low | $163.55 | $2.68 |
Enterprise Value | $84.56B | $1.05B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.51, up 0.39% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company reported strong fiscal 2026 results with revenue of $10.34 billion and net income of $1.81 billion, supported by robust profitability margins. Analyst consensus is a 'Buy' with a $225.83 price target, though valuation multiples like a P/E of 41.81 suggest premium pricing. Recent news highlights dividend declarations and institutional buying interest.
Outlook remains positive given consistent earnings outperformance and upward revenue guidance, but risks include high valuation sensitivity and economic cyclicality. The stock offers growth potential from operational efficiency and market share gains, yet investors should weigh elevated multiples against sector peers.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
